Anima Biotech is advancing in Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against diseases closely linked to protein translation, such as Fibrosis, Respiratory Syncytial Virus, Oncology (C-Myc translation inhibitors) and Huntington’s Disease. The company’s Translation Control Discovery Platform technologies are comprised by Proprietary Analysis (Big data algorithms, Hit selection, validation and de-risking); Breakthrough Biology (from labeled tRNA library to Pathway translation and target identification), and Cloud Architecture (private and secure cloud-based system to implement end-to-end fully automated screening and analysis process). Anima’s Translation Control Therapeutics platform is strategically designed for partnering with Pharma for the discovery and development of translation inhibitors for several targets.